Cg Oncology Inc. Earnings

Cg Oncology Inc.’s revenue jumped 45500% since last year same period to $0.46Mn in the Q4 2024. On a quarterly growth basis, Cg Oncology Inc. has generated 960.47% jump in its revenue since last 3-months.

Cg Oncology Inc.’s net profit fell -97.31% since last year same period to $-31.8Mn in the Q4 2024. On a quarterly growth basis, Cg Oncology Inc. has generated -55.83% fall in its net profits since last 3-months.

Cg Oncology Inc.’s net profit margin jumped 99.57% since last year same period to -6973.25% in the Q4 2024. On a quarterly growth basis, Cg Oncology Inc. has generated 85.31% jump in its net profit margins since last 3-months.

Cg Oncology Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.46 - a -35.06% fall from last quarter’s estimates.

Cg Oncology Inc.’s earning per share (EPS) estimates for the current year stand at -0.46.

Cg Oncology Inc.’s earning per share (EPS) fell -45.06% since last year same period to -0.48 in the Q4 2024. This indicates that the Cg Oncology Inc. has generated -45.06% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Cg Oncology Inc.’s return on assets (ROA) stands at -0.15.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Cg Oncology Inc.’s return on equity (ROE) stands at -0.19.